Test Bank for Tietz Fundamentals of Clinical Chemistry and Molecular Diagnostics 8th Edition by Nader Rifai | Latest Update 2026 Exam Prep Graded A+

Test bank for Tietz Fundamentals of Clinical Chemistry
and Molecular Diagnostics,
8th Edition by Nader Rifai, PhD
Chapters 1 - 49

,Tietz Fundamentals of Clinical Chemistry and Molecular Diagnostics 8th Edition Test Bank

Table of contents:
I. Principles Of Laboratory Medicine
Chapter 1. Clinical Chemistry, Molecular Diagnostics, and Laboratory Medicine
Chapter 2. Selection and Analytical Evaluation of Methods — With Statistical Techniques
Chapter 3. Clinical Evaluation of Methods
Chapter 4. Evidence-Based Laboratory Medicine
Chapter 5. Establishment and Use of Reference Values
Chapter 6. Specimen Collection, Processing, and Other Preanalytical Variables
Chapter 7. Quality Management
II. Analytical Techniques And Instrumentation
Chapter 8. Principles of Basic Techniques and Laboratory Safety
Chapter 9. Optical Techniques
Chapter 10. Electrochemistry and Chemical Sensors
Chapter 11. Electrophoresis
Chapter 12. Chromatography
Chapter 13. Mass Spectrometry
Chapter 14. Enzyme and Rate Analyses
Chapter 15. Immunochemical Techniques
Chapter 16 Automation
Chapter 17. Point-of-Care Instrumentation
III. Analytes
Chapter 18. Amino Acids, Peptides, and Proteins
Chapter 19. Serum Enzymes
Chapter 20. Tumor Markers and Cancer Genes
Chapter 21. Kidney Function Tests — Creatinine, GFR, Urea, and Uric Acid
Chapter 22. Carbohydrates
Chapter 23. Lipids, Lipoproteins, Apolipoproteins, and Other Cardiac Risk Factors
Chapter 24. Electrolytes and Blood Gases
Chapter 25. Hormones
Chapter 26. Catecholamines and Serotonin
Chapter 27. Vitamins, Trace Elements, Nutritional Assessment
Chapter 28. Hemoglobin, Iron, and Bilirubin
Chapter 29. Porphyrins and Porphyrias
Chapter 30. Therapeutic Drugs and Their Management
Chapter 31. Clinical Toxicology
Chapter 32. Toxic Metals
IV. Pathophysiology
Chapter 33. Diabetes

,Chapter 34. Cardiovascular Disease
Chapter 35. Kidney Disease
Chapter 36. Physiology and Disorders of Water, Electrolyte, and Acid-Base Metabolism
Chapter 37. Liver Disease
Chapter 38. Gastrointestinal and Pancreatic Diseases
Chapter 39. Disorders of Bone and Mineral Metabolism
Chapter 40. Disorders of the Pituitary Gland
Chapter 41. Disorders of the Adrenal Cortex
Chapter 42. Thyroid Disorders
Chapter 43. Reproduction-Related Disorders
Chapter 44. Pregnancy and Prenatal Testing
Chapter 45. Newborn Screening and Inborn Errors of Metabolism
Chapter 46. Pharmacogenetics
V. Molecular Diagnostics
Chapter 47. Principles of Molecular Biology
Chapter 48. Nucleic Acid Techniques and Applications
Chapter 49. Genomes and Nucleic Acid Alterations

, Chapter FD.01: FD.Clinical FD.Chemistry, FD.Molecular FD.Diagnostics, FD.and FD.Laboratory FD.Medicine
FD.TestFD
B
. ank




MULTIPLE FD.CHOICE

1. An FD.individual FD.working FD.in FD.a FD.clinical FD.chemistry FD.laboratory FD.is FD.married FD.to FD.a FD.sales
FD.representative FD.who FD.works FD.for FD.a FD.company FD.that FD.sells FD.chemistry FD.laboratory
FD.supplies. FD.When FD.the FD.laboratory FD.manager FD.requests FD.a FD.list FD.of FD.needed FD.supplies, FD.cost
FD.of FD.supplies, FD.and FD.vendors, FD.this FD.individual FD.onlyFD r. ecommends FD.the FD.spouse’s FD.company
FD.as FD.the FD.vendor. FD.This FD.is FD.considered FD.to FD.be FD.a(n):

a. accounting FD.issue.
b. possible FD.conflict FD.of FD.interest.
c. maintenance FD.of FD.confidentiality FD.issue.
d. problem FD.with FD.resource FD.allocation.

ANS: F D . B
Concern FD.has FD.been FD.raised FD.over FD.the FD.interrelationships FD.between FD.practitioners FD.in FD.the
FD.medical FD.fieldFDa. nd FD.commercial FD.suppliers FD.of FD.drugs, FD.devices, FD.equipment, FD.etc., FD.to FD.the
FD.medical FD. profession.

Similarly, FD.relationships FD.have FD.been FD.scrutinized FD.between FD.clinical FD.laboratorians FD.and
FD.manufacturers FD.and FD.providers FD.of FD.diagnostic FD.equipment FD.and FD.supplies. FD.These

FD.concerns FD.led FD.the FD.National FD.Institutes FD.of FD.Health FD.(NIH) FD.in FD.1995 FD.to FD.require FD.official

FD.institutional FD.review FD.of FD.financial FD.disclosure FD.by FD.researchers FD.and FD.management FD.of

FD.situations FD.in FD.which FD.disclosure FD.indicates FD.potentialFD c. onflicts FD.of FD.interest.

DIF: 1 REF: FD. FD. FD.Page FD.4-5 OBJ: F D . 6 FD.| FD.7

2. A FD.patient FD.visits FD.her FD.physician FD.stating FD.that FD.her FD.prescribed FD.painkiller FD.is FD.not
FD.working FD.to FD.reduce FD.the FD.pain FD.following FD.her FD.recent FD.surgery. FD.A FD.friend FD.of FD.the
FD.patient FD.claims FD.that FD.the FD.same FD.painkillerFD
“. worked FD.wonders” FD.to FD.reduce FD.her FD.pain
FD.after FD.the FD.same FD.surgery. FD.The FD.physician FD.states FD.that FD.the FD.difference FD.in FD.the FD.effect

FD.of FD.the FD.drug FD.might FD.be FD.caused FD.by , FD.which FD.is FD.studied FD.in
FD.pharmacogenetics.

a. epidemiology
b. an FD.inherited FD.disease
c. a FD.conflict FD.of FD.interest
d. a FD.genetic FD.variation FD.in FD.drug-metabolizing FD.enzymes

ANS: F D . D
Pharmacogenetics FD.is FD.the FD.study FD.of FD.the FD.genetic FD.variation FD.of FD.drug
FD.metabolism FD.betweenFDi. ndividuals.

DIF: 1 REF: FD. FD. FD.Page FD.3 OBJ: F D . 1

3. John FD.works FD.in FD.a FD.molecular FD.diagnostics FD.laboratory FD.and FD.receives FD.a FD.blood FD.sample
FD.that FD.has FD.the FD.name FD.of FD.a FD.close FD.friend FD.printed FD.on FD.the FD.bar-coded FD.label. FD.The
FD.genetic FD.test FD.that FD.is FD.ordered FD.on FD.theFDf. riend’s FD.sample FD.would FD.provide FD.diagnostic
FD.information FD.about FD.a FD.disorder FD.that FD.has FD.a FD.poor FD.prognosis, FD.and FD.the FD.test FD.is

FD.usually FD.performed FD.by FD.John. FD.He FD.asks FD.a FD.fellow FD.employee FD.to FD.analyzeFD t. he FD.sample
FD.for FD.him FD.and FD.not FD.divulge FD.the FD.results. FD.This FD.ethical FD.issue FD.concerns:

a. confidentiality FD.of FD.patient FD.genetic FD.and FD.medical FD.information.
b. a FD.conflict FD.of FD.interest.